Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023 16:05 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing...
Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
March 01, 2023 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for...
Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference
February 28, 2023 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for...
Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
February 07, 2023 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for...
Viridian Appoints Scott Myers as President and Chief Executive Officer
February 06, 2023 07:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 02, 2023 16:05 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing...
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
January 08, 2023 08:00 ET
|
Viridian Therapeutics, Inc
- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results – - Among 3 mg/kg VRDN-001 treated...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2023 16:05 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing...
Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for...
Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
December 21, 2022 07:00 ET
|
Viridian Therapeutics, Inc
- The global THRIVE Phase 3 trial will be conducted in approximately 50 centers across North America and Europe - - Topline results for the THRIVE Phase 3 trial are expected in the middle of 2024 – ...